Big Pharma Split Corp.

QUARTERLY PORTFOLIO DISCLOSURE

as at September 30, 2020

Total Assets

The total assets of the Big Pharma Split Corp. was \$22,150,247 and includes the value of the Preferred Shares.

Summary of Investment Portfolio

Sector Allocation	% of Total Assets
Pharmaceuticals	79.6
Biotechnology	20.2
Total Portfolio Assets	99.8
Cash and other assets and liabilities	1.1
Foreign currency forwards	(0.9)
Total Asset Value	100.0

Portfolio Allocation	% of Total Assets
Common Shares	70.7
ADRs	29.5
Equity options	(0.4)
Total Portfolio Assets	99.8
Cash and other assets and liabilities	1.1
Foreign currency forwards	(0.9)
Total Asset Value	100.0

Portfolio Breakdown

Top Holdings	% of Total Assets
Amgen Inc.	10.8
Johnson & Johnson	10.3
Eli Lilly and Company	10.2
Merck & Co., Inc.	10.1
AstraZeneca PLC	10.0
Sanofi S.A.	9.9
Bristol-Myers Squibb Company	9.9
Pfizer Inc.	9.9
GlaxoSmithKline PLC	9.6
AbbVie Inc.	9.5
Cash and other assets and liabilities	1.1
Equity options	(0.4)
Foreign currency forwards	(0.9)

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. This quarterly update is available on our website at <u>www.harvestportfolios.com</u>.

Customer Service

416.649.4541 Toll: 1.866.998.8298 Address 610 Chartwell Road Suite 204 Oakville, ON L6J 4A5



Your trusted source for income and growth investments